RCUS vs RYTM Stock Comparison

RYTM currently leads RCUS in this stock comparison, with AIQ scores of 62 vs 39. The clearest difference is momentum.

Market data as of Nov 15, 2026 market close· AIQ score gap 23 points
RCUS
Healthcare
vs
RYTM
Healthcare
RCUS
Arcus Biosciences, Inc.
Price
$17.43
Day move
-1.91%
AIQ Score
39/100
Best edge
Balanced
Sector
Healthcare
RYTM
Rhythm Pharmaceuticals, Inc.
Leads
Price
$115
Day move
+4.7%
AIQ Score
62/100
Best edge
Momentum
Sector
Healthcare

What is the main difference between RCUS and RYTM?

RYTM leads the current stock comparison as Rhythm Pharmaceuticals, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Arcus Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 64/66 fields· High confidence
AIQ VerdictStableAIQ Comparison Conviction 9/10

RYTM leads

RYTM leads by 23 AIQ points, primarily on Momentum and Quality, and the lead has widened from 7 points over 30 sessions. Wall Street currently favors RCUS on target upside.

Stable: 5 of 6 evidence groups support RYTM, its lead is widening, and its current signal state is conflicted.

Evidence agreement: 5 of 6Comparison trend: Strengthening
RCUS

Arcus Biosciences, Inc.

AIQ Score
39/100
AIQ Edge Score
2/10
RYTM

Rhythm Pharmaceuticals, Inc.

Leads
AIQ Score
62/100
AIQ Edge Score
7/10

The Algovestiq AIQ Score currently favors RYTM over RCUS, 62 versus 39 as of Nov 15, 2026. RYTM's advantage is driven primarily by stronger momentum and quality. RYTM also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors RCUS. 5 of 6 covered evidence groups favor RYTM today, and the comparison is rated Stable on stability: the leader is throwing conflicting signals. RYTM lead: Strengthening — the AIQ differential moved from 7 to 23 points over 30 sessions. RYTM leads on all four AIQ factor dimensions. Value is itself one of those four, so a sweep is not explained by valuation alone — it deserves additional scrutiny for unmodeled catalysts, expectations or event risk.

Compare Arcus Biosciences, Inc. and Rhythm Pharmaceuticals, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

RCUS
-52.8%
RYTM
+858.5%

Price return comparison

Growth of $10,000, price only

RCUS $4,722 · RYTM $95,850

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare RCUS and RYTM against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

RCUS advantage
0
RYTM advantage
  • Momentum34 vs 72
    RYTM +38
  • Quality41 vs 60
    RYTM +19
  • Risk Resilience42 vs 57
    RYTM +15
  • Value43 vs 52
    RYTM +9

5 of 6 evidence groups favor RYTM. RYTM’s edge is concentrated in momentum and quality.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

RCUS0 AIQ

Largest factor move: Value +2, not enough on its own to move the overall score.

New signals

  • ADX Trend Strengthening — neutral, trend, medium horizon
RYTM+2 AIQ

Largest factor move: Momentum +4

New signals

  • ADX Trend Strengthening — neutral, trend, medium horizon

RYTM's lead widened by 2 AIQ points in the latest session.

Deeper signal detail for each name lives on its own signals page — RCUS and RYTM both carry a full feed there.

The central trade-off

RYTM (Rhythm Pharmaceuticals, Inc.): the stronger current systematic profile, led by momentum and quality.

RCUS (Arcus Biosciences, Inc.): the counter-case, on analyst expectations.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

RYTM

RYTM on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

RYTM

RYTM on combined revenue and EPS growth.

Value

RYTM

RYTM on the peer-relative Value factor, by 9 points.

Momentum

RYTM

RYTM on the Momentum factor, by 38 points.

Lower downside

RYTM

RYTM on Risk Resilience, by 15 points.

Analyst upside

RCUS

RCUS on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors RYTM, analyst targets favor RCUS. That disagreement is the most useful thing on this page.

MeasureRCUSRYTMNote
Implied upside to target+161%+18.5%RCUS has more room
Target dispersion+19.8%+28.6%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering1519Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

5 of 6 covered evidence groups favor RYTM. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreRYTM39 vs 62
FundamentalsRYTMon balancerevenue growth -78% vs 29.3%; EPS growth -38.9% vs 16.4%; TTM ROE -35.8% vs -20.5%; gross margin 95% vs 88.2%; operating margin -4.7% vs -66.7% — RYTM takes 3 of 5 decided legs, not all of them
ValuationRYTMValue 43 vs 52
TechnicalsRYTMPrice vs 50-day -22.9% vs 18.7%; vs 200-day -28.8% vs 18.3%
Risk ResilienceRYTMRisk Resilience 42 vs 57
Analyst expectationsRCUSTarget upside 161% vs 18.5%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of RCUS and RYTM and are excluded from the count.

AIQ Decision Stability

Stable

The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.

  • The AIQ gap is wide at 23 points. (supports the conclusion holding)
  • 5 of 6 covered evidence groups point the same way. (supports the conclusion holding)
  • The leader's advantage has been widening. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on RYTM.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

RYTM lead: Strengthening — the AIQ differential moved from 7 to 23 points over 30 sessions.

May 27RCUS leads above the line · RYTM leads belowNov 13
Today
RYTM +23
39 vs 62
7 sessions ago
RYTM +19
38 vs 57
30 sessions ago
RYTM +7
48 vs 55
90 sessions ago
RYTM +4
58 vs 62

The lead changed hands 2 times in this window, most recently on Jul 24 when RCUS moved ahead of RYTM.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

RCUS

0 bullish / 3 bearish / 2 neutral

Only RCUS

  • 52-Week Low Proximity — bearish, risk_regime, long horizon (0.0%)
  • Downtrend Structure Active — bearish, trend, long horizon
RYTMConflicted

3 bullish / 3 bearish / 2 neutral, conflicted

Only RYTM

  • Beta Spike Warning — bearish, risk_regime, long horizon
  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • Keltner Channel Breakout — bullish, volatility, short horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.64x)
  • TRIX Bullish Signal — bullish, momentum, short horizon

Both carry 3 more signals that do not separate them: Death Cross Active, ADX Trend Strengthening, ATR Expansion - Breakout Mode.

RYTM leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

RCUSNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.91%, AIQ 0 points).

RYTMConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +4.7%, AIQ +2 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1RCUS closes the Momentum gap — currently 38 points behind, the largest single contributor to RYTM's edge.
  2. 2RCUS's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3RYTM's conflicting signal state resolves bearish — it currently carries 3 bullish and 3 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

RYTM leads on balance
MetricRCUSRYTM
Revenue growth (YoY)-78%29.3%
EPS growth (YoY)-38.9%16.4%
Gross margin95%88.2%
Operating margin-4.8%-66.7%
Return on equity (TTM)-35.8%-20.5%
Debt to equity0.320.02

Performance

RYTM leads 6 of 6 windows
MetricRCUSRYTM
1 week (5 sessions)-4.6%2.4%
1 month (20 sessions)-21.2%33.5%
3 months (63 sessions)-41%-0.4%
6 months (126 sessions)-26.7%27.1%
Year to date-26.9%7.5%
1 year (252 sessions)-12.9%17.5%

Technicals

RYTM has the stronger structure
MetricRCUSRYTM
RSI (14)35.166.3
ADX (14)29.628.5
Price vs 50-day-22.9%18.7%
Price vs 200-day-28.8%18.3%
Volatility (1M, annualized)92.2%110.9%

Risk

RYTM is the more resilient
MetricRCUSRYTM
Beta1.561.24
Sharpe ratio0.050.52
Sortino ratio0.070.89
Max drawdown-44.8%-35.5%
Current drawdown-44.8%-2.2%
Annualized volatility62.7%54.6%
Value at risk (95%)-6.2%-5%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, RCUS or RYTM?

On the Algovestiq AIQ Score, RYTM is the stronger of the two as of Nov 15, 2026, scoring 62 against RCUS's 39. The edge comes from momentum and quality. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is RCUS or RYTM the better buy right now?

RYTM carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Stable — 5 of 6 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.

Why does the AIQ Score favor RYTM over RCUS?

The composite weights Quality, Value, Momentum and Risk Resilience. RYTM leads Momentum by 38 points; RYTM leads Quality by 19 points; RYTM leads Risk Resilience by 15 points. RYTM leads on all four AIQ factor dimensions. Value is itself one of those four, so the sweep is not explained by RCUS simply being cheaper — it warrants extra scrutiny for unmodeled catalysts, forward expectations or event risk the factors do not capture.

Which has more analyst upside, RCUS or RYTM?

Analyst price targets imply +161% upside for RCUS and +18.5% for RYTM, so the Street currently favors RCUS. That points the opposite way to the AIQ Score, which favors RYTM. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, RCUS or RYTM?

RYTM is the better-valued of the two on the peer-relative Value factor. RYTM on the peer-relative Value factor, by 9 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, RCUS or RYTM?

RYTM on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, RCUS or RYTM?

RYTM on the Momentum factor, by 38 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, RCUS or RYTM?

RYTM is the more resilient of the two, so the other name carries the higher downside risk. RYTM on Risk Resilience, by 15 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is RCUS more profitable than RYTM?

The profitability evidence is mixed: gross margin 95% vs 88.2%; operating margin -4.7% vs -66.7%; ttm roe -35.8% vs -20.5%. RCUS leads on two measures and RYTM on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is RYTM's lead over RCUS getting stronger or weaker?

RYTM lead: Strengthening — the AIQ differential moved from 7 to 23 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands 2 times in that window, most recently on 2026-07-24, when RCUS moved ahead of RYTM.

What would change the RCUS vs RYTM verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: RCUS closes the Momentum gap — currently 38 points behind, the largest single contributor to RYTM's edge; RCUS's Death Cross Active resolves — a bearish trend rule currently active against it; RYTM's conflicting signal state resolves bearish — it currently carries 3 bullish and 3 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about RCUS and RYTM?

RCUS: 0 bullish / 3 bearish / 2 neutral. RYTM: 3 bullish / 3 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on RCUS is Death Cross Active (bearish, long horizon). On RYTM it is Death Cross Active (bearish, long horizon).

Compare RCUS and RYTM with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.